Saltar para: Posts [1], Pesquisa e Arquivos [2]

http://cyto.blogs.sapo.pt

Espaço de publicação e discussão sobre oncologia. GBM IMMUNOTHERAPY ONCO-VIRUS ONCOLOGY CANCER CHEMOTHERAPY RADIOTHERAPY


Terça-feira, 21.07.15

clinical study data on ImmunTraCkeR assay in the Journal for ImmunoTherapy of Cancer

 

ImmunID announces publication of clinical study data on ImmunTraCkeR assay in the Journal for ImmunoTherapy of Cancer

Published on July 8, 2015 at 10:02 AM 

ImmunID today announced the publication of a short report in the Journal for ImmunoTherapy of Cancer (JITC) showing that the analysis of peripheral T cell receptor diversity using the company's ImmunTraCkeR® assay is associated with clinical outcomes following Ipilimumab treatment in metastatic melanoma. Results from the study, conducted at Memorial Sloan Kettering Cancer Center, were first presented at the SITC 2014 Annual Meeting.

Study results suggest that ImmunTraCkeR® may ultimately be used as a companion diagnostic for immune checkpoint agents, to determine eligibility to the treatment.

"We are delighted to have been selected by the JITC editorial board for publication. ImmunID's mission is to add precision to the immuno-oncology revolution by personalizing immunotherapy. A large multicenter study is currently underway (Predict-ID Melanoma, France) with the aim to validate prediction capabilities of ImmunTraCkeR® for response to immune checkpoint inhibitors. This is an area of high unmet medical need and could be game-changing for patients," said Bernhard Sixt, ImmunID's Chairman and Chief Executive Officer.

Autoria e outros dados (tags, etc)

por cyto às 18:06

Sexta-feira, 26.06.15

Vaxon Biotech receives new patent in Japan for cancer vaccine candidates

Vaxon Biotech receives new patent in Japan for cancer vaccine candidates

Published on June 22, 2015 at 9:21 AM ·

The company’s worldwide cancer vaccines patent portfolio, made up of ten patent families, now comprises 24 issued patents

Vaxon Biotech, a company specialized in anti-tumor immunotherapy, today announces that it has been granted a new patent in Japan. This patent (JP application n°2012-502822) covers a series of optimized cryptic peptides to be used in the design of the Vbx-026, a new cancer vaccine for solid tumors.

This patent gives Vaxon exclusive rights in Japan and raises its worldwide portfolio to 24 issued patents.

The patent will support the development of Vbx-026, a vaccine dedicated to the treatment of cancer patients expressing the HLA-A24 molecule. This molecule is widely expressed in the Asian population, mainly in Japan, with more than 40% of the Japanese population expressing HLA-A24. The initiation of preclinical development of the Vbx-026 vaccine is planned for 2016.

“This new patent will strengthen our position in Japan, a promising market for the development of the Vbx-026 vaccine,” said Dr. Kostas Kosmatopoulos, CEO of Vaxon Biotech. “With four cancer vaccines under development, ranging from lead optimization to phase II, we have built a strong patent portfolio and we now cover the three major HLA molecules, corresponding to around 80% of cancer patients.”

Vaxon Biotech develops therapeutic vaccines against cancer, based on its proprietary technology of optimized cryptic peptides, which are protected by ten patent families. All vaccines developed by Vaxon target universal tumor antigens and therefore have wide-ranging applications in cancer treatment.

Vx-001 and Vx-006 are already in clinical trials (Vx-001 in an ongoing randomized phase II trial in eight European countries and Vx-006 in an ongoing phase I trial). Vbx-016 has successfully completed its preclinical development and is ready to enter clinical trials and Vbx-026 is at the final stage of lead optimization.

Vx-001 and Vx-006 can be used for the treatment of patients expressing HLA-A2, the most common HLA molecule in humans (40-45% of the world population). Vx-001 and Vx-006 are fully protected by a total of 17 patents granted in Europe, the US, Canada, China and Japan. These patents belong to four patent families and cover peptide optimization technology, the products derived from this technology and their use. Six of these patents belong to INSERM/IGR and have been licensed to Vaxon Biotech, while the remaining 11 are Vaxon’s own property.

Vbx-016 can be used for the treatment of patients expressing HLA-B7, a common HLA molecule (25% of the population). Vbx-016 is already protected by three patent families. Five patents are already granted in Europe, the US, China and South Korea. Additional patents are still under review. All these patents are Vaxon’s own property.

The global market for cancer vaccines is expected to grow to $4.3 billion (€3.8 billion) by 2019, with a five-year compound annual growth rate (CAGR) of 1.3%. Technological advancements, new product launches and unmet treatment needs are predicted to drive consistent growth in this market for the foreseeable future.

Autoria e outros dados (tags, etc)

por cyto às 00:58


Mais sobre mim

foto do autor


Subscrever por e-mail

A subscrição é anónima e gera, no máximo, um e-mail por dia.

Pesquisar

Pesquisar no Blog  

calendário

Fevereiro 2016

D S T Q Q S S
123456
78910111213
14151617181920
21222324252627
2829